Current Status of Perioperative Therapy in Muscle-Invasive Bladder Cancer and Future Directions.
Dillon C CockrellTracy L RosePublished in: Current oncology reports (2023)
The recent approval of nivolumab as adjuvant therapy established a new treatment option for high-risk patients with muscle-invasive bladder cancer after radical cystectomy. Several phase II studies of chemo-immunotherapy combinations and immunotherapy alone have reported pathological complete responses in the 26-46% range, including studies in cisplatin-ineligible patients. Randomized studies of perioperative chemo-immunotherapy, immunotherapy alone, and enfortumab vedotin are ongoing. Muscle-invasive bladder cancer remains a challenging disease associated with significant morbidity and mortality; however, increasing options in systemic therapy and an increasingly personalized approach to cancer treatment suggest continued future improvements in patient care.
Keyphrases
- muscle invasive bladder cancer
- current status
- phase ii
- open label
- clinical trial
- case control
- end stage renal disease
- cardiac surgery
- photodynamic therapy
- double blind
- ejection fraction
- newly diagnosed
- patients undergoing
- combination therapy
- phase iii
- cancer therapy
- peritoneal dialysis
- stem cells
- randomized controlled trial
- replacement therapy
- cell therapy
- mesenchymal stem cells